-
Innovation Ranking
NewInnovation Ranking – Check Point Software Technologies Ltd
Check Point Software Technologies Ltd (Check Point) provides cyber security solutions to government and corporate enterprises. It also develops, and markets products and technologies to secure communications and transactions over internet by enterprises and consumers. Check Point offers a portfolio of network security, endpoint security, data security, and management solutions. The company offers its products and services to enterprises, service providers, small and medium-sized businesses, financial services, government, education, and consumers. Check Point sells its products through a network of...
-
Company Insights
Innovation and Patenting activity of Check Point Software Technologies Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Check Point Software Technologies Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Thematic Analysis
NewEnterprise Security Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Artificial intelligence (AI) is a double-edged sword in cybersecurity. It can help organizations improve their threat detection, hunting, and incident response capabilities, but adversaries can and will use AI in cyberattacks. There is every likelihood that AI will spur new merger and acquisition (M&A) deals in cybersecurity, especially of companies judged to be AI specialists. In the thematic screen of GlobalData’s enterprise security software sector scorecard, AI has a weighting of 20%, higher than any other theme.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Transformed Mycosis Fungoides
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Transformed Mycosis Fungoides report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Transformed Mycosis Fungoides Drug Details: AFM-13 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in B-Cell Non-Hodgkin Lymphoma Drug Details: AFM-13 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Cutaneous T-Cell Lymphoma Drug Details: AFM-13 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acimtamig in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acimtamig in Peripheral T-Cell Lymphomas (PTCL) Drug Details: AFM-13 is...